The mission of gene therapy: the long march from rare disease drugs to mainstream drugs

In recent years, the pharmaceutical industry policies have been continuously introduced.
Consistency evaluation, China's accession to ICH, MAH implementation, and drug clinical trial data verification have accelerated the survival of the fittest in the industry; medical, medical insurance, and pharmaceutical linkages have accelerated medical reform; the industry structure will accelerate reshaping
.
Driven by the reform of medical policies, the development of China's pharmaceutical industry is entering a standardized fast lane
.
In the context of the rise of "healthy China" as a national strategy, China is undergoing a transformation from a "medicine power" to a "medicine power"
.
As one of China's seven strategic emerging industries, the biomedical industry is becoming a new engine for China's economic development
.
Through the regulation of policies, the investment of supporting resources, and the improvement of system and mechanism construction, China's biomedical industry has transitioned from "technologically backward" to "keep up with the international pace", and the development of innovative drugs is particularly rapid
.
A number of innovative biopharmaceutical companies have emerged, such as BeiGene, Cinda Bio, Nuocheng Jianhua, etc.
, and innovative drugs developed independently have been approved for listing
.
If you want to maintain rapid development, you need more top talents to join and the overall level of employees to improve
.
To provide a free and unobstructed communication platform for innovative drug practitioners, Sina Pharmaceuticals specially launched the "Xinzhihui" online live knowledge sharing platform, which will focus on target discovery in drug research and development, new technology development and application, process development and verification, and drug clinical practice.
Hot topics such as experimental design, through strategy and case sharing, directly address the puzzles in R&D and production
.
On October 19 (Tuesday), the 15th issue of "Xinzhihui" opened, Dr.
Xiao Xiao, Chairman of Faith Medicine shared "The mission of gene therapy: the long march from rare disease drugs to mainstream drugs", looking forward to your participation
.
Sharing topics: The mission of gene therapy: the long march from rare disease drugs to mainstream drugs 1) Background introduction of gene therapy 2) Gene therapy drug delivery system 3) R&D direction and technical advantages and bottlenecks 4) Evaluation of safety and effectiveness 5 ) The industry's springing up and the blue sea and the red sea Speaker: Dr.
Xiao Xiao, Chairman of Faith Pharmaceuticals Live time: October 19, 2021 19:30-20:30 Dr.
Xiao Xiao, Chairman and Chief Scientist of Faith Pharmaceutical Technology (Shanghai) Co.
, Ltd.
Zeng He is the Distinguished Chair Professor of the University of North Carolina, and the professor of the School of Pharmacy/School of Bioengineering, East China University of Science and Technology
.
For many years, he has served as a member of the editorial board of many important international academic journals and a judge of the NIH Fund of the United States.
He has served as a board member of the American Society of Gene and Cell Therapy
.
Professor Xiao Xiao has made a number of scientific research results in the development and application of gene vectors and has been widely used, including the improvement of recombinant adeno-associated virus (AAV) gene vectors, high-titer and high-purity AAV production technology, and simple and efficient gene vectors Targeted technology and the development of genetic drugs for hereditary muscle diseases, hemophilia, lysosomal storage diseases, and autoimmune diseases
.
As a co-founder, Professor Xiao Xiao founded gene therapy companies such as Askbio, Bamboo and Faith Medicine
.
The mini-dystrophin gene therapy drug for the treatment of Duchenne muscular dystrophy (DMD) invented in its laboratory has been clinically transformed by Pfizer Pharmaceuticals, and is currently preparing to enter the phase III clinical phase in the United States
.
Registration: This course is free and open.
Scan the QR code below to add Sina Medical Live Assistant to get the live link
.
(Remarks: name + company) For more content sharing in the follow-up, please pay attention to the [Sina Medicine] public account
.